Abstract 442P
Background
The number of permanent colostomies performed for rectal cancer is decreasing as trans-anal excision has become the first-choice surgical approach. However, the types of support required for patients who undergo permanent colostomies according to their courses are not elucidated. This study aims to identify the types of support needed by elderly permanent colostomy patients by the postoperative months and investigated how these affected their quality of life.
Methods
This study was performed by a hypothesis testing approach using an anonymous self-administered questionnaire, which were left with the participants, and 335 members of A Ostomy Association were recruited to participate. The questionnaire had three components: 11 original items about care needed by individuals with colostomies, the Ostomate QOL Survey and the SF-12v2. Basic respondent characteristics were totaled by simple tabulation, and correlation and multiple regression analyses were performed to investigate how the number of postoperative months affected the support that the individuals with permanent colostomies wished for, and how the support they wished for affected QOL. The survey period was September 2017. This study was approved by the research ethics committee of the institution.
Results
Data from 137 participants of the mean age of 76.5 years were included in the analysis. The analysis on how support individuals felt needed with permanent colostomies affected their QOL resulted in significant correlations between “Factors related to daily life” , “Physical condition” (β=-.294, p=.011), “Activity” (β=-.267, p=.011) and “Mental and emotional condition” (β=-.410, p=.000). The multiple regression analysis on the support that individuals with permanent colostomies wanted and health-related QOL resulted in significant associations between “Factors related to daily life” and “Roles in daily life ((β=-.285, p=.014) ,(β=-.363, p=.001).
Conclusions
This study suggested that there were differences in the support that elderly with permanent colostomies wanted depending on the number of months or years passed since their colostomy surgery. Furthermore, it showed that the more they wished for care related to their daily life and health-related QOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
JAPS Grant-in-Aid for Scientific Research(B):25293443.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract